奈捷生物科技股份有限公司Instant NanoBiosensors (INB) is an innovative life sciences company that has developed next generation, cost-effective ultra-sensitive real-time immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platform , Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents ( US, UK, Europe, China, Japan and Taiwan) for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations (5 orders) in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry or other capital instrument . The business opportunity includes co-development, method technology transfer, technology licensing, and IVD applications. We hope to build more strategic partnership with international associates to achieve the mission of FOPPR inside.
We are executing a multinational innovation program, called as “UREKA GlobalStars Taiwan digital industrial collaborations”, in partnership with Centre for Process Innovation (CPI), a British technology and innovation social enterprise, for the purpose of enabling UK industrial digital companies to access, collaborate with and find new markets in Taiwan. Meanwhile, we are in collaboration with global research institutes including Stanford medical center, Brigham and Women's Hospital, Amsterdam UMC, New Castle and University College London in healthcare field. This can help us to provide the information of third-party verification of our technology to pharmaceutical companies so that we can accumulate our capability abundantly for future out-licensing transaction.
奈捷生技
奈捷全球研發總部位於南港國家生技園區
歐洲子公司：荷蘭 Utrecht
美國商務拓展實驗室: San Francisco
ISO 13485/ QMS 廠:汐止
公司有兩個事業體
1.基因部門：院內建置精準醫療,建置精準醫療的設備、試劑、軟體分析,院內建置: 從樣本分析到報告輸出的一站式次世代基因檢測,目前已將平台銷售至國內與國際醫學中心與國際試劑大廠等單位合作
2.蛋白質部門：阿茲海默血液檢測
從全世界500多個生技公司中脫穎而出，更成為德國默克藥廠 2020年亞洲唯一入選的策略性
合作夥伴。因獨特的光纖微流體奈米晶片技術，僅憑 3步驟就能完成頂尖實驗室水準的蛋白
質分析與偵測。「光感測生物指標檢測儀」是以光纖結合奈米粒子與微流體做為快捷感測器，
採用全球首創技術 FOPPR與 IN-CHIP(Auto-Flowing Chip)多國專利可應用於醫療診斷，可
將檢測時間從 3小時大幅縮短到幾分鐘，該產品也因應抗體藥物與免疫治療發展趨勢，具精
準醫療伴隨式檢測與藥物治療評估之潛力。
International Media Interview:
*2021 年7月科技部 TTA季刊專訪http://www.instantnano.com/contents/news?id=45
*2020年8月『商業周刊』專訪 https://www.businessweekly.com.tw/Archive/Article?StrId=7002224
*2020年7月環球生技月刊新銳公司專訪 https://www.gbimonthly.com/2020/08/78143/
*2020 年1月 Merck Innovation Center 官網報導 https://reurl.cc/XWKLbM
*2020 年1月 Journal Publication in EE Times Asia：Detecting Biomarkers With Optical-Fiber
https://www.eetasia.com/news/article/Detecting-Biomarkers-With-Optical-Fiber